
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1568774
This article is part of the Research Topic Urothelial Neoplasms: An Integrated Approach to Prevention, Diagnostics, and Personalized Therapy View all articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
To explore the risk factors and construct a prediction model of the lymphovascular invasion (LVI) in patients with upper tract urothelial carcinoma (UTUC) .Methods Clinical data of 143 UTUC patients treated in our hospital during Jan. 2010 and Dec. 2022 were retrospectively analyzed. The patients were divided into LVI positive group and LVI negative group according to the postoperative lymphovascular conditions. Kaplan-Meier method was used to evaluate the overall survival (OS) and cancer-specific survival (CSS) of the two groups, and the survival curve was drawn.The correlation between LVI and inclusion indexes was analyzed using univariate and ultivariate, and a new model was established. A prediction model was established and receiver operating characteristic (ROC) curve was drawn to analyze the diagnostic value.The median survival time of LVI positive patients was 78 months , lower than the 90months (95%CI 72.77-107.23) for LVI negative patients, and the 5-year OS of LVI positive patients was 53.0%, lower than that of LVI negative patients (79.6%). The difference was statistically significant (P=0.005). The 5-year CSS of LVI positive patients was 57.0%, lower than that of LVI negative patients (85.7%, P=0.009). The results of univariate analysis showed that there were statistically significant differences between the two groups (P < 0.05) in exfoliation cytology (P=0.044), hydronephrosis (P=0.015), preoperative fibrinogen level (P=0.003), lymph node status (P=0.014), pathological stage (P=0.001) and grade (P=0.047). Multivariate Logistic regression analysis showed that hydronephrosis (P=0.022), pathological stage (P < 0.001), lymph node status (P=0.025) and fibrinogen level (P=0.019) were independent factors influencing the occurrence of lymphovascular invasion, and the combination of four indexes above was better than any single index. the ROC curve showed that the area under the curve (AUC) of postoperative LVI was the largest when combined with the four predictors, and the AUC was 0.833 (95%CI 0.759-0.907). When the Youden index was was 0.594, the sensitivity was 81.1%, and the specificity was 78.3%.Lymphovascular invasion is related to hydronephrosis, pathological stage, lymph node condition and fibrinogen level. Patients with preoperative hydronephrosis, high pathological stage, lymph node metastasis and high fibrinogen level were at higher risk of lymphovascular invasion.
Keywords: Upper tract urothelial carcinoma, nephroureterectomy, lymphovascular invasion, Risk factors, Prediction model
Received: 30 Jan 2025; Accepted: 06 Mar 2025.
Copyright: © 2025 Qinghui, Jiantao and Jinhui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Sun Jiantao, Department of General Surgery, Luoyang Central Hospital, Luoyang, China
Yan Jinhui, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.